Your browser doesn't support javascript.
loading
Modulation of drug-linker design to enhance in vivo potency of homogeneous antibody-drug conjugates.
Pabst, Martin; McDowell, William; Manin, Anaïs; Kyle, Andrew; Camper, Nicolas; De Juan, Elena; Parekh, Vimal; Rudge, Felicity; Makwana, Hiteshri; Kantner, Terrence; Parekh, Hemal; Michelet, Aurelie; Sheng, XiaoBo; Popa, Gina; Tucker, Carolyn; Khayrzad, Farzad; Pollard, Derek; Kozakowska, Katarzyna; Resende, Ricardo; Jenkins, Alan; Simoes, Fabio; Morris, Dave; Williams, Paul; Badescu, George; Baker, Matthew P; Bird, Matthew; Frigerio, Mark; Godwin, Antony.
Afiliação
  • Pabst M; Abzena plc., Babraham Research Campus, CB22 3AT Cambridge, United Kingdom. Electronic address: martin.pabst@abzena.com.
  • McDowell W; Abzena plc., Babraham Research Campus, CB22 3AT Cambridge, United Kingdom.
  • Manin A; Abzena plc., Babraham Research Campus, CB22 3AT Cambridge, United Kingdom.
  • Kyle A; Abzena plc., Babraham Research Campus, CB22 3AT Cambridge, United Kingdom.
  • Camper N; Abzena plc., Babraham Research Campus, CB22 3AT Cambridge, United Kingdom.
  • De Juan E; Abzena plc., Babraham Research Campus, CB22 3AT Cambridge, United Kingdom.
  • Parekh V; Abzena plc., Babraham Research Campus, CB22 3AT Cambridge, United Kingdom.
  • Rudge F; Abzena plc., Babraham Research Campus, CB22 3AT Cambridge, United Kingdom.
  • Makwana H; Abzena plc., Babraham Research Campus, CB22 3AT Cambridge, United Kingdom.
  • Kantner T; Abzena plc., Babraham Research Campus, CB22 3AT Cambridge, United Kingdom.
  • Parekh H; Abzena plc., Babraham Research Campus, CB22 3AT Cambridge, United Kingdom.
  • Michelet A; Abzena plc., Babraham Research Campus, CB22 3AT Cambridge, United Kingdom.
  • Sheng X; Abzena plc., Babraham Research Campus, CB22 3AT Cambridge, United Kingdom.
  • Popa G; Abzena plc., Babraham Research Campus, CB22 3AT Cambridge, United Kingdom.
  • Tucker C; Abzena plc., Babraham Research Campus, CB22 3AT Cambridge, United Kingdom.
  • Khayrzad F; Abzena plc., Babraham Research Campus, CB22 3AT Cambridge, United Kingdom.
  • Pollard D; Abzena plc., Babraham Research Campus, CB22 3AT Cambridge, United Kingdom.
  • Kozakowska K; Abzena plc., Babraham Research Campus, CB22 3AT Cambridge, United Kingdom.
  • Resende R; Abzena plc., Babraham Research Campus, CB22 3AT Cambridge, United Kingdom.
  • Jenkins A; Abzena plc., Babraham Research Campus, CB22 3AT Cambridge, United Kingdom.
  • Simoes F; Abzena plc., Babraham Research Campus, CB22 3AT Cambridge, United Kingdom.
  • Morris D; Abzena plc., Babraham Research Campus, CB22 3AT Cambridge, United Kingdom.
  • Williams P; Abzena plc., Babraham Research Campus, CB22 3AT Cambridge, United Kingdom.
  • Badescu G; Abzena plc., Babraham Research Campus, CB22 3AT Cambridge, United Kingdom.
  • Baker MP; Abzena plc., Babraham Research Campus, CB22 3AT Cambridge, United Kingdom.
  • Bird M; Abzena plc., Babraham Research Campus, CB22 3AT Cambridge, United Kingdom.
  • Frigerio M; Abzena plc., Babraham Research Campus, CB22 3AT Cambridge, United Kingdom. Electronic address: mark.frigerio@abzena.com.
  • Godwin A; Abzena plc., Babraham Research Campus, CB22 3AT Cambridge, United Kingdom.
J Control Release ; 253: 160-164, 2017 05 10.
Article em En | MEDLINE | ID: mdl-28257988
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Oligopeptídeos / Imunoconjugados / Antineoplásicos Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Revista: J Control Release Assunto da revista: FARMACOLOGIA Ano de publicação: 2017 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Oligopeptídeos / Imunoconjugados / Antineoplásicos Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Revista: J Control Release Assunto da revista: FARMACOLOGIA Ano de publicação: 2017 Tipo de documento: Article